Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GLYSET vs DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.
Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
treatment of symptomatic benign prostatic hyperplasia (BPH),combination therapy for BPH
50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.
One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function (creatinine clearance >60 m L/min). Clinical context: No accumulation occurs with twice-daily dosing in normal renal function; half-life is prolonged in renal impairment (up to 18 hours in end-stage renal disease).
Dutasteride: Terminal half-life ~5 weeks (3-7 weeks), allowing once-daily dosing; steady-state reached at 3-6 months. Tamsulosin: Terminal half-life ~9-13 hours in healthy subjects, prolonged in elderly (up to 16-19 hours).
Not metabolized; excreted unchanged primarily in feces (51% as unchanged drug, 35% as metabolites) and urine (2-5% as unchanged drug).
Dutasteride is extensively metabolized by CYP3A4 and CYP3A5; tamsulosin is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4.
Primarily excreted unchanged in the urine (renal elimination accounts for >95% of absorbed dose). Fecal elimination is negligible (<2%).
Dutasteride: 40% as metabolites in feces (mainly via bile), 5% in urine. Tamsulosin: 76% in urine as unchanged drug and metabolites, 24% in feces.
Protein binding is very low (approximately 5-10%), primarily to albumin, with no significant binding to other plasma proteins.
Dutasteride: >99.5% bound to albumin and alpha-1-acid glycoprotein. Tamsulosin: 94-99% bound to alpha-1-acid glycoprotein.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution mainly in extracellular fluid and minimal tissue binding.
Dutasteride: Vd 300-500 L (total body, large tissue distribution). Tamsulosin: Vd 0.2 L/kg (approx 14-30 L, moderate distribution).
Oral bioavailability is <2% for the parent compound due to extensive metabolism by intestinal bacteria; however, the active metabolite (miglitol-like) has high local activity. Systemic absorption is minimal (1-2%), consistent with its site of action in the gut.
Dutasteride: Oral bioavailability ~60% (enhanced with food). Tamsulosin: Oral bioavailability ~30% (increased with food; formulation designed for consistent absorption).
Contraindicated if GFR < 25 m L/min/1.73 m². No adjustment needed for GFR ≥ 25 m L/min/1.73 m².
No dosage adjustment is required for renal impairment. Tamsulosin is extensively metabolized and renally excreted as inactive metabolites; however, no specific GFR-based adjustments are recommended.
No specific guidelines; use caution in Child-Pugh class B or C due to limited data.
Dutasteride is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). For mild to moderate hepatic impairment (Child-Pugh A or B), no dosage adjustment is recommended, but caution is advised.
Not recommended for pediatric patients due to lack of safety and efficacy data.
Safety and efficacy in pediatric patients have not been established. Use is not recommended in patients under 18 years of age.
Initiate at lowest dose (50 mg three times daily); titrate cautiously due to age-related renal decline.
No specific dose adjustment is required based on age alone. Elderly patients may be more sensitive to orthostatic hypotension from tamsulosin; monitor blood pressure and advise caution when rising from a seated or lying position.
None
None
Hypoglycemia when used in combination with sulfonylureas or insulin (must be treated with glucose, not sucrose),Gastrointestinal adverse effects (abdominal pain, diarrhea, flatulence) due to undigested carbohydrates fermenting in the colon,Hepatotoxicity (rare, monitor liver enzymes),May cause loss of glycemic control if used with intestinal disorders
Orthostatic hypotension/syncope, especially with concurrent antihypertensives,Intraoperative floppy iris syndrome during cataract surgery,Risk of high-grade prostate cancer (increased Gleason score 8-10 with dutasteride),Hepatic impairment may increase exposure,Sexual dysfunction: decreased libido, erectile dysfunction, ejaculation disorders
Diabetic ketoacidosis,Inflammatory bowel disease,Colonic ulceration,Partial intestinal obstruction,Predisposition to intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Cirrhosis,Hypersensitivity to miglitol
Hypersensitivity to dutasteride, tamsulosin, or other 5α-reductase inhibitors,Women who are or may become pregnant (risk of fetal harm due to androgen inhibition),Severe hepatic impairment (Child-Pugh Class C),History of orthostatic hypotension
Avoid high-sucrose or fructose-containing foods and drinks as GLYSET inhibits the digestion of sucrose, leading to increased fermentation and gastrointestinal distress. Complex carbohydrates (starches) are affected; simple sugars like glucose are not.
Absorption of tamsulosin is decreased when taken with food; however, the combination product should be taken 30 minutes after a meal to maintain consistent exposure. Avoid grapefruit juice as it may increase tamsulosin concentrations. No specific food interactions with dutasteride.
Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.
Dutasteride is contraindicated in pregnancy due to risk of fetal harm, particularly male genital abnormalities (e.g., hypospadias) from inhibition of dihydrotestosterone. Tamsulosin has no known teratogenic risk. First trimester: Dutasteride exposure may cause feminization of male fetuses. Second and third trimesters: Risk persists; avoid use.
Excreted in human milk; M/P ratio unknown. Caution in nursing mothers due to potential for GI effects in infants.
Unknown if dutasteride or tamsulosin are excreted in human milk. Dutasteride is lipophilic and may appear in milk. Tamsulosin likely excreted. M/P ratio not available. Due to potential for adverse effects (e.g., hypotension), breastfeeding is not recommended during therapy.
No dose adjustment recommended based on pharmacokinetic data; monitor glycemic control closely and adjust as needed.
No dose adjustment studies in pregnancy. Dutasteride should not be used; tamsulosin is not recommended. No pharmacokinetic changes requiring dose adjustment are established, but avoid use.
GLYSET (miglitol) is an alpha-glucosidase inhibitor that delays carbohydrate digestion, reducing postprandial hyperglycemia. It is not effective for fasting hyperglycemia and should not be used as monotherapy for type 1 diabetes or DKA. Monitor liver function tests; rare hepatotoxicity reported. Avoid in patients with inflammatory bowel disease or intestinal obstruction.
Dutasteride/tamsulosin is a fixed-dose combination for benign prostatic hyperplasia (BPH). Dutasteride is a 5α-reductase inhibitor that reduces prostate volume over months; tamsulosin is an α1-adrenoceptor antagonist providing rapid symptom relief. Do not split or crush capsules. Avoid use in women and children. Monitor for orthostatic hypotension, especially when initiating therapy. Assess for drug-drug interactions: CYP3A4 inhibitors (e.g., ketoconazole) increase dutasteride exposure; tamsulosin interacts with other α-blockers, antihypertensives, and PDE5 inhibitors. Counsel patients about risk of postural hypotension and syncope. Advise patients to avoid driving or hazardous activities until they know how the medication affects them. Dutasteride may cause sexual dysfunction (decreased libido, ejaculatory dysfunction, gynecomastia). Tamsulosin may cause intraoperative floppy iris syndrome during cataract surgery; inform ophthalmologist of use. Monitor serum PSA levels: dutasteride decreases PSA by ~50% after 6 months; establish new baseline. Do not use in patients with history of prostate cancer.
Take with the first bite of each main meal to delay carbohydrate absorption.,Common side effects include flatulence, diarrhea, and abdominal discomfort, which often improve over time.,If hypoglycemia occurs, use glucose tablets or milk, not sucrose or fruit juice, as GLYSET prevents sucrose breakdown.,Monitor blood glucose regularly, especially when starting or changing dose.,Do not skip meals; take medication exactly as prescribed.
Take this medication once daily, 30 minutes after the same meal each day.,Swallow capsules whole; do not crush, chew, or open.,Rise slowly from sitting or lying down to avoid dizziness or fainting.,Avoid driving or operating machinery until you know how the drug affects you.,Inform your doctor if you plan to have cataract surgery, as this drug may cause complications.,Do not donate blood while taking this medication, as it may harm a fetus if given to a pregnant woman.,Women who are pregnant or may become pregnant should not handle crushed or broken capsules.,Report any breast lumps, pain, or nipple discharge, as gynecomastia is possible.,Use condoms if your partner is pregnant, as dutasteride can be absorbed through skin contact with semen.,Keep all appointments for PSA blood tests; the test result will be lower than expected.,Do not take other alpha-blocker medications for blood pressure or prostate problems while on this drug unless prescribed.,Grapefruit juice may increase side effects; limit or avoid consumption.,Do not stop taking this medication suddenly without consulting your doctor.
No interactions on record
"Tamsulosin, an alpha-1 adrenergic antagonist, and fosinopril, an ACE inhibitor, both lower blood pressure through distinct mechanisms, leading to additive hypotensive effects. This synergistic action increases the risk of orthostatic hypotension, dizziness, syncope, and falls, particularly at treatment initiation or dose escalation. The interaction is of clinical concern in elderly patients or those with volume depletion."
"Lofexidine, a central alpha-2 adrenergic agonist, reduces sympathetic outflow and can cause bradycardia and hypotension. Tamsulosin, an alpha-1 adrenergic receptor antagonist, also lowers blood pressure, especially orthostatic. Combined use leads to additive hypotensive effects, increasing risk of symptomatic bradycardia, orthostatic hypotension, syncope, and falls, particularly at therapy initiation or dose titration."
"The combination of tamsulosin and moexipril can lead to an increased risk of hypotension and orthostatic hypotension due to additive vasodilatory effects. Tamsulosin, an alpha-1 adrenergic antagonist, reduces peripheral vascular resistance, while moexipril, an ACE inhibitor, decreases angiotensin II production, further promoting vasodilation. This synergistic effect may cause symptomatic hypotension, dizziness, and syncope, particularly at the initiation of therapy or during dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GLYSET vs DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, answered by our medical review team.
GLYSET is a Alpha-Glucosidase Inhibitor Antidiabetic that works by Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.. DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is a Alpha-1 Blocker that works by Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GLYSET and DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GLYSET is: 50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.. The standard adult dose of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is: One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GLYSET and DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GLYSET is classified as Category C. Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.. DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is classified as Category A/B. Dutasteride is contraindicated in pregnancy due to risk of fetal harm, particularly male genital abnormalities (e.g., hypospadias) from inhibition of dihydrotestosterone. Tamsulosi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.